[go: up one dir, main page]

AU2002229611A1 - Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells - Google Patents

Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells

Info

Publication number
AU2002229611A1
AU2002229611A1 AU2002229611A AU2961102A AU2002229611A1 AU 2002229611 A1 AU2002229611 A1 AU 2002229611A1 AU 2002229611 A AU2002229611 A AU 2002229611A AU 2961102 A AU2961102 A AU 2961102A AU 2002229611 A1 AU2002229611 A1 AU 2002229611A1
Authority
AU
Australia
Prior art keywords
modulating
receptor
active compounds
compounds capable
langerhans cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229611A
Inventor
Veronique Angeli
Monique Capron
Francois Trottein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut Pasteur de Lille
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut Pasteur de Lille
Publication of AU2002229611A1 publication Critical patent/AU2002229611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002229611A 2000-12-08 2001-11-08 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells Abandoned AU2002229611A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00403453 2000-12-08
EP00403453 2000-12-08
PCT/EP2001/014205 WO2002045718A1 (en) 2000-12-08 2001-11-08 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells

Publications (1)

Publication Number Publication Date
AU2002229611A1 true AU2002229611A1 (en) 2002-06-18

Family

ID=8173975

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229611A Abandoned AU2002229611A1 (en) 2000-12-08 2001-11-08 Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells

Country Status (2)

Country Link
AU (1) AU2002229611A1 (en)
WO (1) WO2002045718A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003851A (en) * 2002-02-22 2004-07-08 Taisho Pharmaceutical Co Ltd Antipruritics.
CN100408039C (en) 2002-08-09 2008-08-06 大正制药株式会社 Antipruritics
US7737182B2 (en) 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
US7321001B2 (en) 2002-12-20 2008-01-22 Amgen Inc. Asthma and allergic inflammation modulators
KR20100102668A (en) 2007-12-19 2010-09-24 암젠 인크 Phenyl acetic acid derivatives as inflammation modulators
CA2839102A1 (en) * 2011-06-29 2013-01-03 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
CN115393351B (en) * 2022-10-27 2023-01-24 北京大学第三医院（北京大学第三临床医学院） Method and device for judging cornea immune state based on Langerhans cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201788A (en) * 1976-10-20 1980-05-06 University Patents, Inc. Process for alleviating proliferative skin diseases
AU2690684A (en) * 1984-02-24 1985-09-10 Kenji Adachi Methods and pharmaceutical compositions for the treatment of hyperplastic diseases of the skin
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Compositions for topical treatment of psoriasis and atopic dermatitis comprising a xanthine derivative
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
WO1997022586A1 (en) * 1995-12-15 1997-06-26 Merck Frosst Canada Inc. Tri-aryl ethane derivatives as pde iv inhibitors
AU3440697A (en) * 1996-07-02 1998-01-21 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
JPH11199478A (en) * 1998-01-05 1999-07-27 Hiroshi Nagoshi Use of retinoid and prostaglandin d2 derivative as antiinflammatory agent
WO1999062555A1 (en) * 1998-06-03 1999-12-09 Shionogi & Co., Ltd. Remedies for itching containing pgd2 antagonists
CA2369910A1 (en) * 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
WO2002045718A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001290250A1 (en) Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
AU2003213151A1 (en) Controlled release solid dosage carbamazepine formulations
AU2001234114A1 (en) Drugs containing combined active ingredients
AU2001277741A1 (en) 2-aminopyridine compounds and use thereof as drugs
HUP0202757A3 (en) Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
AU2002217373A1 (en) Controlled release pharmaceutical formulation containing venlafaxine
AU2001292185A1 (en) Formulation containing amoxicillin
AU2002306708A1 (en) In situ langerhans cell vaccine
AU6440600A (en) Combination of active agents, said combination containing clonidine
AU2001248833A1 (en) Stable liquid preparation
AU2002245754A1 (en) Fluid dispenser with fluid weight monitor
AU2001288114A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
AU6386801A (en) System for the release of active ingredients
AU2002229611A1 (en) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
AU2001248772A1 (en) Sustained release drug compositions
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AU4431400A (en) Anticancer agents containing ep1 antagonists as the active ingredient
AU2002212629A1 (en) Compounds active at the glucocorticoid receptor iii
AU2001229920A1 (en) Pill dispenser with alarm
AU2023801A (en) Dihalopropenyloxybenzene derivatives and pesticides containing the same as the active ingredient
AU2003259532A1 (en) Ready-to-drink formulation containing an active ingredient
AU3382001A (en) Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance